EUCTR2009-017251-94-SE进行中（未招募）不适用
Efficacy and safety of BF2.649 in the treatment of Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnoea syndrome (OSA), refusing the nasal continuous positive airway pressure (nCPAP) therapy - HAROSA II
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Bioprojet
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and/or female outpatients aged from at least 18 years of age
- •-Polysomnography
- •-Patients refusing to be treated by nCPAP therapy, and still complaining of Excessive Daytime Sleepiness
- •-Epworth Sleepiness scale = 12
- •-Beck Depression Inventory 13 items (BDI-13 items): score < 16 and item G = 0
- •-Mini Mental State Examination (MMSE) ? 28
- •-Body Mass Index (BMI) ? 40 Kg/m2
- •-Female patients with child-bearing potential using a medically accepted method of birth control
- •-If specified by the investigator, the patient must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the trial, or as long as the investigator deems it clinically indicated. In addition, patients should be willing to maintain during the study their usual behaviours which could affect their diurnal sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration).
- •-Patients having signed and dated the informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Patients suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA
- •Patients with co-existing narcolepsy (ICSD 2005)
- •Patients with sleep debt not due to OSA
- •Patients with non-respiratory sleep fragmentation
- •Shift work - professional drivers
- •Refusal from the patient to stop any current therapy for excessive daytime sleepiness or predictable risk for the patient to stop the therapy
- •Patients suffering from a psychiatric disease
- •Acute or chronic disease preventing the improvement assessment
- •Current or recent (within one year) history of drug, alcohol, narcotic or other substance abuse or dependence.
- •Any significant serious abnormality of the cardiovascular system
- •Severe comorbid medical and biological conditions that may jeopardize study participation at the discretion of the investigator.
- •Positive serological test (optional HIV, HCV and HBsAg)
- •Pregnant or breast-feeding women
- •Women with child-bearing potential and no efficient birth-control method
- •Patients unable to understand the study protocol
- •Patients with suspected or known hypersensitivity to study medication
- •Patients with a dominant arm deficiency impeding the achievement of the tests
- •Patients using a prohibited medication
- •Congenital galactose poisoning, glucose and galactose malabsorption, deficit in lactase
- •Patients participating in another study or being in a follow–up period for another study
- •-Severe hepatic Impairment (e.g. prothrombin ratio < 50% or factor V < 50% for patients receiving anti-vitamin K medication) or with Severe Renal Impairment (e.g. serum creatinine greater than 2.0 mg/dl)
研究者
相似试验
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 100000004852EUCTR2009-017251-94-BGBioprojet280
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017251-94-DKBioprojet280
进行中（未招募）
不适用
Efficacy and safety of BF2.649 in the treatment of Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnoea syndrome (OSA), refusing the nasal continuous positive airway pressure (nCPAP) therapy - HAROSA IIEUCTR2009-017251-94-FIBioprojet280
进行中（未招募）
不适用
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 14.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 100000004852EUCTR2009-017251-94-DEBioprojet280
进行中（未招募）
1 期
The study aims to confirm the effectiveness and safety of BF2.649 over placebo for the treatment of excessive daytime sleepiness associated with Obstructive Sleep Apnoea syndrome in patients who refuse CPAP therapyExcessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapyMedDRA version: 13.1Level: LLTClassification code 10015595Term: Excessive daytime sleepinessSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017251-94-BEBioprojet268